Form 4: Calidi Biotherapeutics CEO Granted Stock Options
SEC Form 4 Filing
Eric Poma, CEO of Calidi Biotherapeutics, receives a grant of 726,412 stock options as an inducement award.
Summary
- Eric Poma, the CEO of Calidi Biotherapeutics, Inc., was granted 726,412 stock options on April 22, 2025.
- The options were approved by the compensation committee and board of directors as an inducement grant.
- The exercise price is $0.4690 per share, equivalent to the closing price of the company's common stock on the grant date.
- 25% of the options vest one year after the grant date, and the remaining 75% vest monthly over the following 36 months, contingent upon continued service.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice, indicating confidence in the CEO and the company's future performance. The vesting schedule promotes long-term commitment.
Positives
- The grant of stock options aligns the CEO's interests with those of the shareholders.
- The vesting schedule incentivizes continued service and commitment from the CEO.
Future Outlook
The vesting schedule suggests an expectation of continued service from the CEO for at least three years.
Industry Context
Granting stock options to executives is a common practice in the biopharmaceutical industry to incentivize performance and align management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Biogen routinely use stock options to incentivize their executives.
- The vesting schedule of 25% after one year and the remainder monthly over three years is a fairly typical arrangement.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it aligns the CEO's interests with theirs.
- Employees may see it as a sign of confidence in the company's leadership and future prospects.
Key Dates
| Date | Description |
|---|---|
| 04/22/2025 | Grant date of the stock options and the date of the earliest transaction. |
| 04/22/2025 | Date the compensation committee and board of directors approved the inducement grant. |
| 04/24/2025 | Date of the power of attorney. |
| 04/22/2035 | Expiration date of the stock options. |
Keywords
stock options, Calidi Biotherapeutics, CEO, Eric Poma, inducement grant, CLDI, Form 4, beneficial ownership, Section 16(a)
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.